Furthermore, proteomic analysis revealed the significant potential of MYH9 in early prediction of GCR childhood nephrotic syndrome, positioning it as a potential candidate biomarker for evaluating glucocorticoid efficacy (32–34). This evidence concerns the gene MYH9 and nephrotic syndrome.